Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis

Heying Pei, Linhong He, Mingfeng Shao, Zhuang Yang, Dan Li, Yuanyuan Zhou, Minghai Tang, Taijin Wang, Yanqiu Gong, Xiaoxin Chen,

Scientific Reports · 2018 · 46 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

Abstract Janus tyrosine kinase 3 (JAK3) is expressed in lymphoid cells and is involved in the signalling of T cell functions. The development of a selective JAK3 inhibitor has been shown to have a potential benefit in the treatment of autoimmune disorders. In this article, we developed the 4-aminopiperidine-based compound RB1 , which was highly selective for JAK3 inhibition, with an IC 50 of value of 40 nM, but did not inhibit JAK1, JAK2 or tyrosine kinase 2 (TYK2) at concentrations up to 5 µM. Furthermore, RB1 also exhibited favourable selectivity against a panel of representative kinases. In a battery of cytokine-stimulated cell-based assays, this potent inhibitor of JAK3 activity with good selectivity against other kinases could potently inhibit JAK3 activity over the activity of JAK1 or JAK2 (over at least 100-fold). A combination of liquid chromatography-mass spectrometry (LC-MS) experiments validated that RB1 covalently modified the unique cysteine 909 residue in JAK3. In vivo , RB1 exerted significantly improved pathology in the joints of a collagen-induced arthritis mouse model. The reasonable pharmacokinetics properties (F = 72.52%, T1/2 = 14.6 h) and favourable results of toxicology experiments (LD 50 > 2 g/kg) suggest that RB1 has the potential to be an efficacious treatment for RA.

References

25